These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 39054386)
1. Oral administration of garlic-derived nanoparticles improves cancer immunotherapy by inducing intestinal IFNγ-producing γδ T cells. Xu J; Yu Y; Zhang Y; Dai H; Yang Q; Wang B; Ma Q; Chen Y; Xu F; Shi X; Liu Z; Wang C Nat Nanotechnol; 2024 Oct; 19(10):1569-1578. PubMed ID: 39054386 [TBL] [Abstract][Full Text] [Related]
2. γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment. Liu J; Wu M; Yang Y; Wang Z; He S; Tian X; Wang H J Transl Med; 2024 Jun; 22(1):553. PubMed ID: 38858763 [TBL] [Abstract][Full Text] [Related]
3. Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment. Cheng CC; Chang J; Ho AS; Sie ZL; Peng CL; Wang CL; Dev K; Chang CC Cancer Immunol Immunother; 2024 Jul; 73(9):175. PubMed ID: 38953994 [TBL] [Abstract][Full Text] [Related]
4. The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity. Chitadze G; Oberg HH; Wesch D; Kabelitz D Trends Immunol; 2017 Sep; 38(9):668-678. PubMed ID: 28709825 [TBL] [Abstract][Full Text] [Related]
5. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application. Miyashita M; Shimizu T; Ashihara E; Ukimura O Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615 [TBL] [Abstract][Full Text] [Related]
6. γδ T cell-based anticancer immunotherapy: progress and possibilities. Meraviglia S; Lo Presti E; Dieli F; Stassi G Immunotherapy; 2015; 7(9):949-51. PubMed ID: 26569071 [No Abstract] [Full Text] [Related]
7. Analysis of cytokine producing activity of intestinal intraepithelial T cells from TCR beta-chain and delta-chain mutant mice. Kohyama M; Hachimura S; Nanno M; Ishikawa H; Kaminogawa S Microbiol Immunol; 1997; 41(4):353-9. PubMed ID: 9159410 [TBL] [Abstract][Full Text] [Related]
8. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice. Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328 [TBL] [Abstract][Full Text] [Related]
9. γδ cells and tumor microenvironment: A helpful or a dangerous liason? Lo Presti E; Di Mitri R; Pizzolato G; Mocciaro F; Dieli F; Meraviglia S J Leukoc Biol; 2018 Mar; 103(3):485-492. PubMed ID: 29345336 [TBL] [Abstract][Full Text] [Related]
10. γδ T cells exhibit multifunctional and protective memory in intestinal tissues. Sheridan BS; Romagnoli PA; Pham QM; Fu HH; Alonzo F; Schubert WD; Freitag NE; Lefrançois L Immunity; 2013 Jul; 39(1):184-95. PubMed ID: 23890071 [TBL] [Abstract][Full Text] [Related]
11. Function of γδ T cells in tumor immunology and their application to cancer therapy. Park JH; Lee HK Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742 [TBL] [Abstract][Full Text] [Related]
12. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer. Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809 [TBL] [Abstract][Full Text] [Related]
13. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner. Hull CM; Larcombe-Young D; Mazza R; George M; Davies DM; Schurich A; Maher J Mol Ther; 2024 Jul; 32(7):2373-2392. PubMed ID: 38745414 [TBL] [Abstract][Full Text] [Related]
14. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925 [TBL] [Abstract][Full Text] [Related]
15. Preclinical platforms to study therapeutic efficacy of human γδ T cells. Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974 [TBL] [Abstract][Full Text] [Related]
16. γδ T cells in cancer immunotherapy. Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972 [TBL] [Abstract][Full Text] [Related]
17. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354 [TBL] [Abstract][Full Text] [Related]
18. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside. Gogoi D; Chiplunkar SV Indian J Med Res; 2013 Nov; 138(5):755-61. PubMed ID: 24434328 [TBL] [Abstract][Full Text] [Related]
19. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells. Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491 [TBL] [Abstract][Full Text] [Related]